These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19896837)

  • 1. HMGA1 protein expression in familial breast carcinoma patients.
    Chiappetta G; Ottaiano A; Vuttariello E; Monaco M; Galdiero F; Gallipoli A; Pilotti S; Jodice G; Siranoush M; Colombo M; Ripamonti CB; Pallante PL; Radice P; Fusco A
    Eur J Cancer; 2010 Jan; 46(2):332-9. PubMed ID: 19896837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression.
    Chiappetta G; Botti G; Monaco M; Pasquinelli R; Pentimalli F; Di Bonito M; D'Aiuto G; Fedele M; Iuliano R; Palmieri EA; Pierantoni GM; Giancotti V; Fusco A
    Clin Cancer Res; 2004 Nov; 10(22):7637-44. PubMed ID: 15569996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low expression of bcl-2 in Brca1-associated breast cancers.
    Freneaux P; Stoppa-Lyonnet D; Mouret E; Kambouchner M; Nicolas A; Zafrani B; Vincent-Salomon A; Fourquet A; Magdelenat H; Sastre-Garau X
    Br J Cancer; 2000 Nov; 83(10):1318-22. PubMed ID: 11044356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
    Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women.
    Noguchi S; Kasugai T; Miki Y; Fukutomi T; Emi M; Nomizu T
    Cancer; 1999 May; 85(10):2200-5. PubMed ID: 10326698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
    Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
    Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
    Rayoo M; Yan M; Takano EA; Bates GJ; Brown PJ; Banham AH; Fox SB
    J Clin Pathol; 2009 Oct; 62(10):896-902. PubMed ID: 19622517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
    Pinilla SM; Honrado E; Hardisson D; Benítez J; Palacios J
    Breast Cancer Res Treat; 2006 Sep; 99(1):85-90. PubMed ID: 16541313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes.
    Loman N; Johannsson O; Bendahl PO; Borg A; Fernö M; Olsson H
    Cancer; 1998 Jul; 83(2):310-9. PubMed ID: 9669814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
    Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
    Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of high-mobility group proteins A1 and A2 represents a valid diagnostic marker in post-pubertal testicular germ cell tumours.
    Franco R; Esposito F; Fedele M; Liguori G; Pierantoni GM; Botti G; Tramontano D; Fusco A; Chieffi P
    J Pathol; 2008 Jan; 214(1):58-64. PubMed ID: 17935122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of HuR in hereditary breast cancer.
    Heinonen M; Fagerholm R; Aaltonen K; Kilpivaara O; Aittomäki K; Blomqvist C; Heikkilä P; Haglund C; Nevanlinna H; Ristimäki A
    Clin Cancer Res; 2007 Dec; 13(23):6959-63. PubMed ID: 18056170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
    Kataki A; Gomatos I; Pararas N; Armakolas A; Panousopoulos D; Karantzikos G; Voros D; Zografos G; Markopoulos C; Leandros E; Konstadoulakis M
    Clin Genet; 2005 Apr; 67(4):322-9. PubMed ID: 15733268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression and prognostic value of HMGA1 in pancreatic head and periampullary cancer.
    van der Zee JA; ten Hagen TL; Hop WC; van Dekken H; Dicheva BM; Seynhaeve AL; Koning GA; Eggermont AM; van Eijck CH
    Eur J Cancer; 2010 Dec; 46(18):3393-9. PubMed ID: 20724141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
    van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
    J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
    Janatova M; Zikan M; Dundr P; Matous B; Pohlreich P
    Hum Mutat; 2005 Mar; 25(3):319. PubMed ID: 15712267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
    Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
    Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathology of BRCA1- and BRCA2-associated breast cancer.
    Honrado E; Benítez J; Palacios J
    Crit Rev Oncol Hematol; 2006 Jul; 59(1):27-39. PubMed ID: 16530420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.